Notice of Proposed Sale · 144
Kura Oncology, Inc.
KURANASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- KURA ONCOLOGY, INC.
- Issuer CIK
- 0001422143
- SEC file number
- 001-37620
- Phone
- (858)-500-8800
- Person for whose account securities are to be sold
- BAIR TERESA BROPHY
- Relationships to issuer
- Officer
- Street
- 4930 Directors Place, Suite 500
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 8,442 | 90,835.92 | 91,869,597 | 09/28/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 09/27/2026 | PSU | Issuer | 8,442 | N | 09/28/2026 | N/A |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| 10b5-1 Sales for Teresa Bair | Restricted Stock Units | 08/19/2026 | 31,487 | 397,829.73 |
Seller — prior-sale row 1, entry 1
- Name
- 10b5-1 Sales for Teresa Bair
- Street
- 4930 Directors Place
- Street (continued)
- Suite 500
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 09/28/2026
- Signed
- /s/ Teresa Bair
Company context
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.